Agenus Inc. - Common Stock (AGEN)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Mar 24, 2026Investment Snapshot
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 89.8% — good return on equity
- Revenue growing at 10% annually
Agenus Inc. - Common Stock (AGEN) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $142 million . Key value metrics: Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Agenus Inc. - Common Stock — Fundamental Analysis Summary
On financial health, AGEN shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 89.8% (sector average: -19.8%).
StockPik's composite Value Score for AGEN is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AGEN reports a high gross margin of 99.1% (sector average: 33.5%) and a negative operating margin of -62.9%.
AGEN shows revenue growing at 10% year-over-year, with earnings growing at 100%.